Carl E. Ruby, Ph.D.
Affiliations: | 2002 | Oregon State University, Corvallis, OR |
Area:
Cell Biology, Environmental Sciences, Molecular Biology, ToxicologyGoogle:
"Carl Ruby"Parents
Sign in to add mentorNancy I. Kerkvliet | grad student | 2002 | Oregon State | |
(Direct effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on antigen -presenting cells and molecular signaling pathways in dendritic cells.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Troyer RM, Ruby CE, Goodall CP, et al. (2017) Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Experimental Cell Research |
Kohlhapp FJ, Broucek JR, Hughes T, et al. (2015) NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal For Immunotherapy of Cancer. 3: 18 |
Kaufman HL, Ruby CE, Hughes T, et al. (2014) Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal For Immunotherapy of Cancer. 2: 11 |
Kim DW, Zloza A, Broucek J, et al. (2014) Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. Journal of Translational Medicine. 12: 113 |
Farazi M, Cohn Z, Nguyen J, et al. (2014) Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell priming. Journal of Leukocyte Biology. 96: 245-54 |
Farazi M, Nguyen J, Goldufsky J, et al. (2014) Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunology, Immunotherapy : Cii. 63: 615-26 |
Broucek J, Hughes T, Huelsmann E, et al. (2014) Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment Journal For Immunotherapy of Cancer. 2 |
Stonewall K, Quintero C, Zloza A, et al. (2013) The impact of age on a mitoxantrone-based tumor vaccine Journal For Immunotherapy of Cancer. 1: P234 |
Vasilevsky NA, Ruby CE, Hurlin PJ, et al. (2011) OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. European Journal of Immunology. 41: 1024-34 |
Jensen SM, Maston LD, Gough MJ, et al. (2010) Signaling through OX40 enhances antitumor immunity. Seminars in Oncology. 37: 524-32 |